Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anavex Life Sciences said signing National Alzheimer’s Project Act (NAPA) into law is a much-needed plan which comprehensively addresses and coordinates federal efforts to enhance Alzheimer’s-related care and services.
Subscribe to our email newsletter
On its part, to potentially help address the disease, the US-based Anavex is advancing ANAVEX 2-73, its lead drug candidate for Alzheimer’s disease.
Reportedly, ANAVEX 2-73 is the first of a new class of oral, disease-modifying drugs being studied to potentially treat Alzheimer’s disease itself, versus treating its symptoms.
On the verge of beginning a Phase I clinical trial in humans, preclinical animal studies have shown early signs of efficacy, improvement in the memory of animals and a disease-modifying effect in some cases.
Anavex Life Sciences executive chairman Cameron Durrant said NAPA is the largest legislative victory in many years for the Alzheimer’s community and they are strong supporters of this new law.
"Our unique approach, which may potentially prevent, halt and/or reverse the course of Alzheimer’s disease, is both exciting and encouraging based on the data we have generated from our extensive preclinical program and as we approach Phase I trials," Durrant said.